新闻&发布

  • 10.02.2015 | Cardiac Researchers at National Heart Centre Singapore Acquire First SyncroPatch 384/768PE in Asia

    Munich, Germany, February 10, 2015; Cardiac Researchers at National Heart Centre Singapore Acquire First SyncroPatch 384/768PE in Asia

    The SyncroPatch 384/768PE is an advanced robotic screening platform that is used to investigate the effects of chemical compounds and toxins on ion channel function. The instrument supports high quality recordings from up to 768 cells simultaneously, allowing high throughput screening of ligand- and voltage-gated ion channels expressed in cell lines, stem cells or patient-derived cells. The SyncroPatch 384PE/768 PE combines high versatility and data quality by offering fast solution exchange, brief compound exposure, internal perfusion and minimal cell usage. The minimal cell usage application improves cost efficiency while allowing screening capabilities with cells of limited availability such as primary cells or otherwise rare and expensive stem cells or patient-derived cells. Nanion’s Patchliner, a high quality, automated patch clamp platform recording from eight cells in parallel, and the CardioExcyte 96, a 96-well plate based platform for contractility and electrical activity measurements from cellular networks, are acknowledged for their utility in cardiac safety and toxicity screening.

    Dr. Winston Shim, Principal Scientist, National Heart Centre Singapore, says:
    “I find the performance and technical capabilities of the SyncroPatch 384/768PE convincing. In particular, the fact that stem cell-derived cardiomyocytes can be measured with reasonable success rates, and the optimized cell handling procedure, which reduces input cell numbers, is appealing when working with patient-derived cardiomyocytes and other clinical samples. Additionally, Nanion’s Patchliner that supports automated current clamp recordings at physiological temperatures is highly attractive when investigating action potentials and drug-induced alterations. In combination with the CardioExcyte 96, it opens the possibility to investigate acute and chronic effects of chemical compounds on beating cardiac syncytium from our work on cardiac maturation. Going forward, I believe that such enabling platforms will galvanize our work in human cardiomyocytes from disease modeling to drug discovery and regenerative medicine.”

    The CiPA initiative, commenced by HESI and the FDA, aims at expanding the mandatory cardiac ion channels from two to five in safety screening efforts, thus demanding higher throughput capabilities and the ability to use stem cell-derived cardiomyocytes in cardiotoxicity screening. Here, Nanion’s APC platforms the SyncroPatch 384/768PE and the Patchliner, constitute an excellent complement to the CardioExcyte 96 covering the range from in vitro cellular network studies to in-depth ion channel safety studies.

    About Nanion Technologies
    Nanion Technologies was founded in 2002 as a spin-off from the University of Munich, Center for Nanoscience (CeNS). Over the last 13 years it has grown to a strong company with over 80 employees worldwide. Nanion has its headquarters in Munich, Germany, and has daughter companies in the USA, Japan and China, with distribution partners in 7 other countries, including Singapore. Nanion has been recognized for its quality and innovation by being twice nominated for the Federal President’s Award for Technology and Innovation (Deutscher Zukunftspreis) in 2007 and 2014. The company has become known for its high quality instruments for ion channel research (Port-a-Patch, Patchliner and SyncroPatch product families) and has over the years expanded its product range to include cardiotoxicity screening (CardioExcyte 96), parallel bilayer recordings (Orbit 16), and parallel membrane transporter protein recordings (SURFE2R). Since 2014, Nanion carries Axion’s multi-electrode array (MEA) systems in Europe and China.

    AAbout Dr. Winston Shim, National Heart Centre Singapore
    NDr Shim has extensive experience in cardiac electrophysiology and regenerative medicine for ischemia and heart failure. He was among the first in the world to demonstrate ex vivo differentiation of human mesenchymal stem cells into cardiomyocytes. His major interest is in cardiac developmental biology and physiology of human cardiomyocytes. His team has extensive experience in the generation of human induced pluripotent stem cells, characterization of human cardiomyocytes and cardiogenic pathways and his group conducts annual hands-on workshops for the stem cell community in Singapore. His group was the first to demonstrate restorative therapy for long QT syndrome 2 in human cardiomyocyte model. In his capacity as Principal Investigator of the National Heart Research Institute Singapore (NHRIS), he established the induced pluripotent stem cell program, cardiac tissue engineering program, regenerative medicine program and launched platform technologies in cardiac electrophysiology, experimental animal modelling, tissue and plastic histopathology, cardiac ultrasound and hemodynamic imaging to spearhead cardiac research in Singapore.

    Contact
    National Heart Centre Singapore, 9th Level, National Heart Research Institute Singapore, 5 Hospital Drive, Singapore 169609.

     

    Download the press release here.

  • 22.01.2015 | Nanion TWIns With Stem Cells as New Facilities Are Opened in Japan and USA

    Tokyo, Japan and Livingston, NJ, USA, January 22, 2015; Nanion is expanding on two continents as new state-of-the-art research and demonstration facilities are opened in Tokyo, Japan and Livingston, NJ, USA. The new facilities provide the opportunity for customers to see Nanion’s entire product portfolio in action, from the Port-a-Patch to the SyncroPatch 384/768PE.

    USA 306x288

    Nanion Technologies, an innovative German-based company providing high quality devices for ion channel research and drug discovery, recently expanded into new premises in both Japan and USA. Nanion Technologies Inc. opened in 2008 and due to expansion of personnel and devices it has now moved to larger premises in Livingston, NJ, with fully equipped laboratory facilities for validation experiments and demonstrations of the entire Nanion product range. Rodolfo Haedo, VP of Nanion Technologies Inc. says about the move:

    Rodolfo Haedo, VP of Nanion Technologies Inc. says about the move:
    ”We are very excited to move to these new, larger and more modern premises. We have had huge interest in the SyncroPatch 384/768PE high throughput screening tool since its launch in 2013 and have an ever-increasing installed base of the instruments in the US. The SyncroPatch 384PE has been so well received by customers so far and we see a bright future for sales this year, as well as for our other Nanion instrumentation in the US. These new premises will give us the opportunity to exhibit our complete product range to its full potential”.

    Japan 306x285

    In Tokyo, Japan, Nanion has opened a new research laboratory within the Tokyo Women’s Medical University - Waseda University Joint Institution for Advanced Biomedical Sciences (TWIns) . TWIns is a leading facility for induced pluripotent stem (iPS) cell research where Nanion has established a close collaboration with the Tokyo Women’s Medical University (TWMU) to combine the use of iPS cells on Nanion’s devices. Customers will be able to visit the facility to see the Nanion platforms in action with cells and receive high-quality support including iPS cardiomyocytes and neurons. Nanion Japan’s expert electrophysiologist and general manager, Atsushi Ohtsuki, says about the new premises:

    “TWIns is a recognized institute for stem cell research with an excellent reputation. Our collaboration with TWMU will enable optimal performance of iPS cells on Nanion’s platform. We will have the full range of Nanion’s products available for scientific support or demonstrations in this new state-of-the-art facility in the heart of Tokyo, and look forward to welcoming both potential and existing customers to visit us here.”

    About Nanion Technologies
    Nanion Technologies is a one-stop-shop for ion channel drug discovery and screening technologies as well as sophisticated research instrumentation. Nanion was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and successfully established four generations of automated patch clamp instruments for sophisticated and high throughput applications in ion channel research and drug discovery (Port-a-Patch, Patchliner and SyncroPatch product families). Further product lines are for cardiotoxicity screening (CardioExcyte 96), for parallel bilayer recordings (Orbit 16), and for parallel membrane transporter protein recordings (SURFE2R). Recently, Nanion’s management team was nominated for the Federal President’s Award for Technology and Innovation (Deutscher Zufunftspreis 2014).


    Download the press release here.

  • 15.10.2014 | Prestigious Academic Facility at Northwestern University Acquires the SyncroPatch 384/768PE

    Livingston, NJ, USA, October 15, 2014; The SyncroPatch 384/768PE offers the highest throughput in automated patch clamping history. The SyncroPatch 384/768PE focuses on providing both high quality recordings together with broad experimental versatility, two important hallmarks that clearly convinced scientific researchers at the Northwestern University Feinberg School of Medicine, Chicago, IL.

    The SyncroPatch 384/768PE is an advanced robotic screening platform that investigates the effects of chemical compounds and toxins on ion channel function. The instrument supports high quality recordings from up to 768 cells simultaneously, allowing high throughput screening of ligand- and voltage-gated ion channels expressed in cell lines, stem cells or patient-derived cells. 
    The SyncroPatch 384PE/768 PE combines high versatility and data quality by supporting fast solution exchange, brief compound exposure, internal perfusion and minimal cell usage. The minimal cell usage application improves cost efficiency while allowing screening capabilities with cells of limited availability such as primary cells or otherwise rare and expensive stem cells or patient-derived cells. Entering the market in 2013, the SyncroPatch 384/768PE was rapidly adopted by renowned pharmaceutical companies, contract research organizations and biotech companies, following a strong trend which includes academic research institutions. Academic core facilities have blossomed all across America over the past years, providing researchers with the ability to run high throughput and high content screens for drug or target discovery that not too long ago was strictly exclusive to Big Pharma and biotech companies. By blending the strength and standardization of Big Pharma with the intelligence and acumen of basic research, core facilities can now contend with more ambitious projects that call for larger resources.

    Dr. Al George, Professor and Chair of Pharmacology at Northwestern University Feinberg School of Medicine, Chicago, IL, USA says:
    “We are extraordinarily excited about installing the first SyncroPatch 384PE in an academic setting in North America. The enormous throughput, intuitive software and robust liquid handling capabilities along with superior seal quality, stability and high success rates convinced us to purchase the instrument. The SyncroPatch 384PE will enable us to perform detailed high throughput analysis of genetic variants in human ion channels at a previously unobtainable scale, and will form the cornerstone of a new HTS facility we are building. We also look forward to upgrading to 768 wells in the near future.”

    Rodolfo Haedo, Vice President Nanion Technologies Inc. continues:
    “The acquisition of the SyncroPatch 384/768PE by the prestigious facility at Northwestern University Feinberg School of Medicine confirms the trend we’re experiencing, that the SyncroPatch 384/768PE is receiving a great deal of attention by the finest scientific research laboratories in the world. We are extremely excited to work with Dr. George and the groups involved at Northwestern University as they work at the interface of ion channel pharmacology and channelopathy research. We will finally have the opportunity to see the implementation of many different applications, ranging from hard-core biophysical characterization of patient-specific ion channel mutations, as well as target directed drug screening for personalized medicine, which in turn will continue to push the boundaries of what to expect from a patch clamp-based HTS system.”

    About Nanion Technologies
    Nanion Technologies is a one-stop-shop for ion channel drug discovery and screening technologies as well as sophisticated research instrumentation. Nanion was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and successfully established four generations of automated patch clamp instruments for sophisticated and high throughput applications in ion channel research and drug discovery (Port-a-Patch, Patchliner and SyncroPatch product families). Further product lines are for cardiotoxicity screening (CardioExcyte 96), for parallel bilayer recordings (Orbit 16), and for parallel membrane transporter protein recordings (SURFE2R). Recently, Nanion’s management team was nominated for the Federal President’s Award for Technology and Innovation (Deutscher Zufunftspreis 2014).

    About Northwestern University Feinberg School of Medicine 
    Northwestern University Feinberg School of Medicine, founded in 1859, attracts talented individuals to its faculty, staff, and student body through its cutting-edge research initiatives, superb clinical affiliates, global outlook, and innovative curriculum. Located in the heart of Chicago’s Magnificent Mile, Feinberg has built a national reputation for excellence through a strong history of collaborative, interdisciplinary medical education and research, and along with Northwestern Memorial Hospital and Northwestern Medical Group is part of the premier academic medical center known as Northwestern Medicine. Feinberg stands out among the nation\"s research-intensive medical schools and consistently receives high marks in U.S. News & World Report surveys. Through its affiliates, it provides patient care to thousands of individuals every year, and plays an integral part in the communities it serves.

    Dr. George is the Magerstadt Professor and Chairman of Pharmacology and Director of the Center for Pharmacogenomics at Northwestern University Feinberg School of Medicine. He is an internationally regarded leader of diseases caused by the disturbed function of ion channels (channelopathies), including those resulting in heart rhythm disorders, such as the congenital long-QT syndrome, and neurological disorders, including epilepsy.

     

    Download the press release here.

  • The Team behind Nanion Technologies Nominated for the Deutscher Zukunftspreis– the Federal President’s Award for Technology and Innovation

    Munich,  Germany,  September  17,  2014;  The  management  team  at  Nanion Technologies is one of three nominees for the Deutscher Zukunftspreis, the German president’s award for technology and innovation. As announced today, the team has been nominated for Nanion’s latest automated screening platform, the SyncroPatch 384/768PE, which enables completely new strategies in drug discovery and scientific research.

     

    As one of the leading industrial nations, Germany is known for its strength in technical innovation and entrepreneurship with a strong focus on product quality.  The Deutscher Zukunftspreis (German Future Award), by which the German Federal President rewards cutting-edge technological innovations, which also  have a high potential for commercial success and societal benefit, is the  country\"s most prestigious award for technology and innovation.

     

    At a press conference in Munich today, the Office of Federal President Joachim Gauck announced the nomination of Nanion Technologies\"  management team for the development and successful market entry of the  SyncroPatch 384/768PE, a chip-based platform allowing high throughput  screening of compounds affecting ion channels. Ion channels are proteins residing in the membranes of cells of the human body. Because ion channel dysfunction underlies diverse diseases and their symptoms, they are highly important both from the basic biomedical science and drug development stand point. The SyncroPatch 384/768PE is the first platform ever to allow functional ion channel screening on a truly industrial scale, with novel possibilities and great potential of bringing new and safe medication to the market faster. Dr. Niels Fertig (CEO), Dr. Andrea Brüggemann (CSO), and Michael George (CTO) are the team behind the project “High Throughput Ion Channel Screening – from the University Bench to Global Player” nominated for this year’s Deutscher Zukunftspreis.

     

    Dr. Niels Fertig, spokesperson, co-founder and CEO of Nanion Technologies, says:

    We are thrilled and feel very honoured to be nominated for the most prestigious award for technology and innovation in Germany, and we look forward to the great event in Berlin where the award winning team will be  announced. Of course we’re biased, but the SyncroPatch 384/768PE clearly has  great potential to revolutionize ion channel screening, thus enabling biotech and pharma companies to bring better drugs to the market at a faster pace.” 

     

    The final winner will be selected by the jury on November 19 in Berlin and will be announced on the evening of that day by Federal President Joachim Gauck, at a major event hosted and broadcasted by the public television channel, ZDF.

     

    About Nanion Technologies:

     

    Nanion Technologies is a one-stop-shop for ion channel drug discovery and screening technologies as well as sophisticated research instrumentation.  Nanion was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and successfully established four generations of automated patch clamp instruments for sophisticated and high throughput applications in ion channel research and drug discovery (Port-a-Patch, Patchliner and SyncroPatch product families). Further product lines are for cardiotoxicity screening (CardioExcyte 96), for parallel bilayer recordings (Orbit 16), and for parallel membran transporter protein recordings (SURFE2R). Since 2014, Nanion carries Axion’s multi-electrode array (MEA) systems in Europe and China. 

     

    Contact details:

     

    Niels Fertig, CEO, Phone: +49 89 2189 97972, Email: info@nanion.de, Web: www.nanion.de

    Press Contacts: Cecilia Farre, Marketing Director, Phone: +49 89 2189 97973, Email: Cecilia@nanion.de

     

    The team nominated for Deutscher Zukunftspreis: Michael George (CTO), Andrea Brüggemann (CSO) and Niels Fertig (CEO).


  • 01.09.2014 | Nanion’s Port-a-Patch Convinces Researchers at the Woods Hole and Cold Spring Harbor Summer Programs

    Livingston, NJ, USA, September 1st, 2014; Nanion visits the prestigious scientific summer programs at the Marine Biological Laboratory in Woods Hole and at Cold Spring Harbor Laboratory, NY, to show the versatility and ease-of-use of the Port-a-Patch. Students and lecturers were very impressed by how the Port-a-Patch makes high quality patch clamp recordings accessible to the user with minimal training.

    The Marine Biological Laboratory (MBL) in Woods Hole, MA and the Cold Spring Harbor Laboratory (CSHL), NY, are world famous institutions in the biosciences spawning Noble-price winning research. Every year a number of prestigious summer programs are hosted, some of the best students and instructors from the USA and around the world gather to further their training and to exchange ideas. This year Nanion was invited to both the Neurobiology course at the MBL (co-directed by Professors Dr. Grame Davis of UCSF and Dr. Timothy A. Ryan of Cornell University) and the Ion Channels and Synaptic Transmission Course at CSHL (co-directed by Professors Dr. Stephan Brenowitz, NIDCD/National Institutes of Health, Dr. Ian Duguid, University of Edinburgh, UK, and Dr. Paul Kammermeier, University of Rochester, USA). Application scientist Dr. George Okeyo and Head of US Lab Operations Dr. Joerg Oestreich, both from Nanion Technologies Inc., ventured out with the Port-a-Patch to demonstrate the versatility and ease-of-use offered by Nanion’s automated patch clams systems. At both institutions, students and instructors alike were impressed with the Port-a-Patch for its ease of use. Here is what some of the participants had to say:

    Dr. Bautista, UC Berkeley, teaching the electrophysiology section in the neurobiology class at MBL said:

    "We are extremely happy about the performance of the Port-a-Patch. We used it for two weeks and very easily trained all the students in the course on it. We had a very high success rate when it came to patching transfected HEK cells, and also managed to obtain recordings from freshly dissociated mouse DRG neurons. We want to thank you again for lending us your instrument, everybody was very impressed."

    Dr. Kammermeier at Cold Spring Harbor Laboratory (CSHL), NY, remarked:

    "Thanks for visiting the Ion Channels and Synaptic Transmission course this summer at the Cold Spring Harbor Laboratory. The course participants enjoyed your demonstration of the Port-a-Patch system and were impressed that you were able to set up and get some recordings in such a short time frame. I can see how this system can be useful, particularly in the simple intracellular solution exchange, something that cannot be so easily done with conventional patch-clamp recording. I think this system may reduce the learning curve for new students to acquire some data, which could allow graduate students doing short lab rotations to get their feet wet quickly in a patch-clamp lab."

    Dr. Amy Lee, Associate Professor in the Departments of Molecular Physiology & Biophysics, Otolaryngology Head-Neck Surgery, University of Iowa, and guest lecturer at the CSHL course:

    "Building an electrophysiology rig is a daunting task for the investigators with little experience with patch-clamp recording techniques. The Port-a-Patch simplifies the task, and allows entry-level patch clampers to obtain high-quality electrophysiological data from a variety of cell-types. With its tiny footprint, the Port-a-Patch is also an excellent solution for small laboratory spaces. Due to the ease with which recordings can be performed, the Port-a-Patch would be ideal for demonstrating general concepts on membrane excitability to students in the teaching or research lab."

    Image Round V1

     


    Port-a-Patch in action at the Neurobiology Course at MBL in Woods Hole. 

    Patch clamp recordings were made on the Port-a-Patch from acutely dissociated neurons. Data courtesy of by Dr. Diana Bautista and Mr. Pellegrino.

     

    by Joerg Oestreich

  • 17.06.2014 | Nanion技术和Axion Biosystem宣布在欧洲和中国成为战略合作伙伴

    慕尼黑,德国,617号,2014Nanion技术,全自动膜片钳平台首要的供应商,和Axion Biosystem,第一个高通量微电极分析系统的创作者,今天宣布在欧洲和中国建立合作关系。Nanion将马上拥有AxionMEA产品,提供广泛的生物医药方面的应用。


    Axion Biosystems 提供最先进的、高分辨率、基于MEA的设备,实验的应用范围从基础细胞电生理到高通量筛选(HTS)。Axion的MEA系统代表了下一代的多电极分析技术,提供了应用于研究自然细胞间电信号和连接通讯的方法。为了满足增长的“disease in a dish”分析和功能安全性筛选的要求,Axion和Nanion今天宣布在欧洲和中国市场成为战略合作伙伴。
    在进一步加强和补充nanion产品种类的同时Nanion将会销售、维修和技术支持Axion的单孔MEA系统、Muse和带有HTS功能的多孔MEA系统Maestro。

    Dr. Niels Fertig, CEONanion公司创始人说我们对AxionMEA系统有极其深刻的印象,因为他们大量的应用领域,从深入的、高分辨率的细胞簇反应到高通量药物筛选。我们认为Axion的产品为我们的全自动膜片钳筛选和基于阻抗的系统提供了非常好的补充,并且看到了巨大的应用前景包括表型筛选、用于表型疾病模型的干细胞、以及神经和心肌毒性安全性检测。除此之外,与Axion的合作将加强我们在电生理药物研究、筛选以及关联领域中作为一站式高效工具的作用。


    Tom O’Brien, Axion Biosystems的 CEO 也说: “NanionAxion一个非常好的合作伙伴,因为我们有着相同的背景和哲学理念,最终体现于具有创新性的产品中。作为公司,我们都有一个坚实的趋于研究和应用的重点,以及在科学和技术发展上的深刻理解和广泛的专业知识。这些特点同眼界结合从而打破限制,开发出与HTS兼容的产品。我们被nanion公司强有力的发展轨迹、极其优秀的客户服务和产品稳定性所吸引。我们为这次合作兴奋,并对Nanion将会成为欧洲和中国市场非常成功的合作伙伴报以极大的信心。


    Nanion技术和Axion  Biosystems将分别于2014年7月1-4号在德国罗伊特林根的MEA会议上和2014年7月4-7号在意大利米兰的2014年FENS会议上一起发布他们的产品。

    点击这里下载发布信。

    点击这里访问产品页面。

    想要进行样机试用或了解关于Mastro和Muse以及耗材的价格,请通过邮件 info@nanion.cn联系我们!


    点击这里进入Axion Bioystem的网站。

  • 25.04.2014 | Nanion receives New Jersey Business Incubation Network’s Award 2014

    North Brunswick, NJ, USA, April 25, 2014; Out of 325 startup companies in NJ, Nanion was selected for NJBIN award and recognized as one of the highest performing companies in the area. The New Jersey Business Incubation Network is a collaborative statewide community of business experts and resource facilities dedicated to enhancing the commercial success of early stage and expansion stage entrepreneurial companies, growing higher paying jobs, and supporting the economic growth strategy for the state.

    Rodolfo Haedo, Vice President Nanion Technologies Inc., says:

    I want to thank the NJBIN and CCIT for nominating us for this award and for the hard work of the US-team allowing us to be here today. We are honored to accept this award!

    Rodolfo Haedo and Joerg Oestreich, Head of US Lab Operations, accepted the NJBIN Award at ceremony on April 25, 2015, held at Rutgers EcoComplex in Bordentown, NJ.

     NJBIN2014 V2


    Rodolfo Haedo thanking for the NJBIN Award, watch the video here:

    Rudi Utube




  • 11.02.2014 | Successful Introduction of a Novel Patch Clamp-Based HTS-System Through Collaboration Between Nanion and Beckman Coulter

    Munich, Germany, February 11, 2014; Nanion recently introduced the SyncroPatch 384 Patch Engine (PE), an instrument for HTS-compatible ion channel screening. As a modular part of the Biomek FX, a state-of-the-art liquid handling robot from Beckman Coulter, the SyncroPatch 384PE allows stable and reliable recordings and ensures swift setup and integration into existing HTS-environments.

    Patch clamp is the gold standard for investigating ion channels and their effectors, but is remotely far from high throughput screening (HTS) standards. During the past decade, great efforts have been made to automate the patch clamping process and thereby overcome its ultra-low throughput, resulting in a handful of medium-throughput automated patch clamp systems.

    Last year the SyncroPatch 384PE was introduced, the first instrument capable of delivering high quality patch clamp data in a 384-well plate format, accompanied by the complete automation of ion channel screening. In this way, the SyncroPatch 384PE allows full integration into HTS-related software, hardware and processes.

    By teaming up with Beckman Coulter, a provider of best-in-class liquid handlers, Nanion could focus solely on the development of the Patch Engine, a patch clamp module with 384 parallel recording channels. Two Patch Engine modules can be integrated per Biomek FX robot, together offering stable whole cell recordings from up to 768 cells in parallel, with average success rates of 85% for completed experiments. The system allows for at least 20,000 data points per day, and is well-suited for both ligand- and voltage-gated ion channels.

     Dr. Christoph Krüll, Marketing Manager EMEAI, Life Science Automation, Beckman Coulter GmbH, says:

    The Biomek FX is a great match for the SyncroPatch 384PE because of its robustness, flexibility and the fact that it is common throughout laboratories worldwide. Additionally, Beckman Coulter’s open software architecture ensures complete integration of SyncroPatch 384PE control functions, facilitating simple and straightforward setup of schedules and routines. The SyncroPatch 384PE provides for an application specific Biomek system and expands the area of use for our products.”

     Dr. Niels Fertig, CEO and founder of Nanion Technologies, continues:

    “The development of the Patch Engine was extremely rapid and relies on proven successful technology and more than 10 years’ experience in product development of automated patch clamp devices. But in addition, the quick development, recent launch and shipping of the system, was to great extent accomplished by using the Biomek FX as primary liquid handling platform. The Biomek FX offers advanced and reliable pipetting options, massively parallel pipetting heads, and the complete integration into existing control software. So for Nanion, most of the liquid handling requirements were a “consider-it-done”-situation with Beckman Coulter as partner.”

    Nanion’s team of application specialists and support technicians work closely together with Beckman Coulter’s global service network, for a swift and seamless integration of the SyncroPatch 384PE into existing HTS environments and to promptly respond to customer requests.

    The SyncroPatch 384PE will be displayed at the Biophysical Society’s annual meeting in San Francisco, CA, February 15-19.


    About Nanion Technologies:

    Nanion Technologies GmbH is a German Private Limited Company and was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and globally established four generations of highly successful automated patch clamp instruments as enabling tools for sophisticated and high throughput applications for ion channel research and drug discovery. Nanion recently launched the CardioExcyte 96, for cardiac safety screening, and the SURFE2R N96, a device for parallel membrane transporter protein recordings.

    Contact:

    Niels Fertig, CEO, Phone: +49 89 2189 97972, Email: info@nanion.de, Web:www.nanion.de



    About Beckman Coulter

    Beckman Coulter Life Sciences’ global leadership and world-class service and support delivers instrument systems, reagents and services to improve workflow and outcomes for researchers in academic and commercial life sciences laboratories, enabling discoveries in biology-based research and development, and solutions for bioprocessing. A leader in centrifugation and flow cytometry, Beckman Coulter also has brought to market innovations in capillary electrophoresis, particle characterization and laboratory automation. Its products are used to further important areas of scientific investigation, including genomics and proteomics.

    For more information, please visit www.BeckmanCoulter.com.

    Beckman Coulter, the stylized logo, and Biomek are trademarks of Beckman Coulter, Inc. and are registered in the USPTO.

    Press Contact:

    Hillary Hunter 
    Public Relations 
    Beckman Coulter Public Relations
     

    hillaryhunter@beckman.com


    +1 (561) 714-7826

  • 17.10.2013 | Port-a-Patch in Education - Promotes Intriguing Neuroscience Research for Undergrad Students at Cedar Crest College

    The Port-a-Patch is often referred to as the world’s smallest patch clamp set-up. It is so small that it can be held in one hand, and at the same time a very powerful and enabling technology with a vast experimental freedom. Port-a-Patch makes patch clamping easier and offers about a tenfold throughput increase compared with the conventional set up. The learning curve is steep, thus allowing patch clamp also in shorter projects.

    Dr. Audrey Ettinger, Director of the Neuroscience Program at Cedar Crest College, has recently invested in a Port-a-Patch for teaching and for neuroscience research projects, intending to investigate the effect of herbal substances as neuroprotective agents in diseases such as stroke. Dissociated neurons from developing chick will be used as model in this study.

    Below are excerpts from the Cedar Crest College press release, as well as a link to the full press release.


    Allentown, Pa. (September 13, 2013) - The National Science Foundation awarded a $186,032 grant to Cedar Crest College that will give biology students the opportunity to work with top-of-the-line instrumentation, providing a competitive edge in the marketplace post-graduation. Associate Professor and Director of the Genetic Engineering Program, K. Joy Karnas, Ph.D., and Associate Professor and Director of the Neuroscience Program, Audrey Ettinger, Ph.D., submitted the proposal to provide their students access to the latest experimental technology and to increase opportunities to collaborate with neighboring colleges and universities in the Lehigh Valley and beyond. This is the first grant that Karnas and Ettinger have received from the National Science Foundation.”

    “In August, representatives from Nanion Technologies installed the Port-a-Patch, a miniaturized patch clamp system that generates cell physiology data quickly and easily. Cedar Crest students will waste no time in utilizing this new technology, as Karnas and Ettinger already have specific research questions in place that students will begin exploring this fall. Students will be investigating the role of herbal remedies as neuroprotective agents for neurons in diseases such as stroke (the third leading cause of death in the United States). Students working under the direction of Ettinger will use dissociated neurons from developing chick embryos to chemically simulate stroke, and then attempt to rescue those neurons using an herbal remedy such as Ginkgo biloba extract. They will study the cells using fluorescence microscopy, and use the newly obtained Port-a-Patch instrument to examine ion channels in those cells.”


    Read the full press release here.

    More information about the Port-a-Patch here.

    More Port-a-Patch data here.

  • 08.10.2013 | Joint Press Release: Tecella Powers Nanion's SyncroPatch 384PE

    FOOTHILL RANCH, CA (Oct 8, 2013) - Nanion selected Tecella\"s Mach amplifier to power their SyncroPatch 384PE automated patch clamp system. The SyncroPatch 384PE (Patch Engine) is the industry\"s highest throughput giga-seal system scalable to 768 channels, and is capable of 20,000 data points per day.

    "The Mach significantly reduced the time-to-market for the SyncroPatch 384PE", states Niels Fertig, Nanion CEO. "With Tecella\"s technology, we are able to deliver a fully parallel system configured as 384-channels or 768-channels."

    With throughput of 20,000 data points per day, the SyncroPatch 384PE aims to accelerate the drug discovery process by enabling high-quality ion channel recordings to be performed during primary screening.

    Nanion\"s SyncroPatch 384PE will be displayed at the Society for Laboratory Automation and Screening (SLAS) 2014 Conference in San Diego from January 18-22, 2014.

    Product information: http://www.nanion.de/products/syncropatch-384pe.html

    About Tecella
    Tecella specializes in the development of patch clamp amplifier systems and digitizers for the advancement of drug discovery. For inquiries regarding this press release, Tecella, please contact:

    Dianne Yamamoto, Business Manager

    Phone: +1-714-641-1709, E-mail: dianne.yamamoto@tecella.com, Web:www.tecella.com

    About Nanion
    Nanion Technologies GmbH is a German Private Limited Company and was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and globally established three highly successful automated patch clamp instruments as enabling tools for sophisticated and high throughput applications for ion channel research and drug discovery.

    Nanion recently launched the CardioExcyte 96, for cardiac safety screening, and the SURFE2R N96, a device for parallel membrane transporter protein recordings.

    Contact details:

    Niels Fertig, CEO, Phone: +49 89 2189 97972, Email: info@nanion.de, Web:www.nanion.de

    Cecilia Farre, Marketing Director, Phone: +49 89 2189 979 73, Email:Cecilia.Farre@nanion.de

  • 24.09.2013 | 耐尼恩公司隆重推出SyncroPatch 384 PATCH Engine(PE)——一种革命性的基于自动膜片钳且实现千兆级封接的离子通道药物筛选的设备


    24.09.2013 | 耐尼恩公司隆重推出SyncroPatch 384 PATCH Engine(PE)——一种革命性的基于自动膜片钳且实现千兆级封接的离子通道药物筛选的设备

    德国慕尼黑时间2013年9月24日, Nanion技术公司发布全新的SyncroPatch 384 Patch Engine(PE),它将推动离子通道药物研发到达一个新高度。以无缝整合全自动药物筛选为设计目标,SyncroPatch 384 PE装有384道膜片钳放大器和先进的384道液体处理机械臂。

    SyncroPatch 384 PE高质量自动膜片钳系统,能够最终将电生理学金标准从离子通道药物的二次筛选推入到一次筛选。每天可以多达20k数据点,它是在高质量离子通道记录平台市场上性能最高的设备。它的效率主要归因于384个细胞完全平行记录、384个加样枪以及超常效率的控制和分析软件。软件和硬件已经被全面测试并且被工业级离子通道药物研发的领先机构认证在真正的离子通道药物高通量筛选中可提供最佳性能。

    已有的自动膜片钳设备都是独立的机器,而和它们相比,SyncroPatch 384 PE是一个模块化设备,专为整合各方面筛选流程自动化而设计。目前最高可以整合两个384道膜片钳模块到一个液体处理机械臂,并行记录768道记录槽。成功率基本都在85%以上,而且液体消耗很低。384个细胞进行一次完整的量效反应分析大概仅需15分钟,每小时可产生数千个数据点


  • 12.09.2013 | Nanion Introduces New Product Family: CardioExcyte 96 for Cardiac Toxicity Profiling and Screening

    Munich, September 12,2013, The CardioExcyte 96 is a high resolution device recording contractility in intact cardiomyocyte networks utilizing non-invasive impedance measurements. The system allows cost-efficient, early compound safety profiling using stem cell-derived cardiomyocytes, freshly dissociated cardiomyocytes or beating 3D-cell clusters.

    Cardiac safety assessment is a vital part of drug development since late withdrawals of compound candidates, due to heart liability issues such as ventricular arrhythmia, are very costly. In-vivo methods give highly relevant information but are extremely low throughput allowing the analysis of only a handful of compounds. In-vitro methods, such as automated patch clamp and other methods, offers higher throughput, however from one type of cardiac ion channels, typically over-expressed in cell lines. Nanion’s new device, the CardioExcyte 96, has the potential to bridge this gap, by allowing reliable label-free measurements of short- and long-term compound effects on the beating pattern of stem cell-derived cardiomyocytes. The system offers the highest impedance time-resolution (sub-millisecond) on the market and records from 96 wells in parallel. Efficiency and ease-of-use are facilitated by an outstanding software package for data handling and export; thus an essential part of the CardioExcyte system.

     Dr. Sonja Stölzle-Feix, Senior Scientist, Nanion Technologies, Munich, says:

    “CardioExcyte 96 is an easy-to-use system, providing impedance-based cardiac safety data from a diversity of stem cell-derived cardiomyocytes. Concentration- and time-dependence of a compound’s potential cardiotoxicity can efficiently be obtained. Further on, the powerful software, used for recordings and analysis, employs comprehensive beat investigation algorithms, displaying detailed beating kinetics in real-time. Data handling and export is straightforward, easy to grasp and yet very, very powerful.”
     Dr. Niels Fertig, CEO of Nanion continues:

    “CardioExcyte is a new branch in Nanion’s product portfolio. This label-free impedance system constitutes an excellent complement to automated patch clamp-based safety screening. It offers cost-efficient and highly relevant data on a drug candidate’s effect on intact networks of beating heart cells. Alteration of beating patterns can give a hint on what cardiac ion channel is affected, which is where detailed electrophysiology investigations take on the further investigations. Cardiac network responses offer a comprehensive view of a compound’s safety profile, without having to use in-vivo methods, and thus save time, costs and suffering.”

     The CardioExcyte 96 is an automated device, recording from 96 wells at a time. With embedded electronics and a sophisticated sensor technology inside the well-plate based consumables, CardioExcyte 96 is a turn-key system for efficient impedance measurements, also allowing recordings residing inside of the incubator. The system has been validated with stem cell derived cardiomyocytes from several providers (Axiogenesis, Cellular Dynamics International, GE Healthcare), as well as beating, 3D-clusters (Cellectis).

     

    For more information about the CardioExcyte 96, click here.

    For the full press release, click here.

  • 29.11.2012 | Nanion自动化脂双层平台Orbit16和Ionera公司的MECA脂双层阵列联合应用可对合成的DNA组成的纳米孔进行功能分析


    慕尼黑&弗莱堡,德国,2012年11月29号;这周在《科学》杂志上有篇标志性的文章发表,使用了Nanion公司新的Orbit16平台和Ionera公司的MECA脂双层阵列芯片,研究人工设计的DNA折叠形成的纳米孔。来自慕尼黑技术大学的Simmel教授的科研小组使用半自主组装的DNA分子纳米结构创造了纳米级跨膜离子通道。这些“设计出来的孔洞”是在脂双层上构建的,使用Orbit16和Ionera公司的MECA阵列芯片就可以同时构建16个脂双层并进行记录。 

    最近,使用离子通道作为分子计数器或纳米孔的分析技术得到极大关注。Obirt平台联合使用MECA脂双层阵列,可以开展纳米孔研究和离子通道重构。Simmel教授的科研小组开拓性的在《科学》杂志上发表了这个工作,人工离子通道已使用DNA折叠的纳米孔被设计出来。此项技术利用了DNA分子,作为可控制的建筑材料来构建用户设计的自组装的纳米级结构,基本可以在标准计算机上设计这些复杂结构。研究者证明这些自组装的纳米结构表现得也很像离子通道。他们确实首次揭示了未来可能使用DNA纳米技术应用于合成细胞膜通道作为分子感受器、抗生素和新的纳米结构的驱动器。 

    为了验证一种潜在应用,研究者使用纳米孔做了数种不同的分子感受器的实验。这就确认了我们是可以记录单个分子通过DNA构成的膜通道,观察电学特征的变化的。因为这个方法可以从结构和化学组成上设计膜通道,它可以为研究两种其他分子感受器家族在生物和纳米孔方面提供极大的优势。

    这种新型的纳米孔已可被nanion公司的自动脂双层记录平台高效精确的分析了。Orbit16使用了Ionera公司的微电极阵列(MECA)。Ionera公司是从弗莱堡大学分离出来的。它通过快速同时形成16个高稳定性的微米级脂双层并且同时记录,极大的加速了整体分析过程。为了自动且同时形成16个脂双层,Orbit使用专利技术(Ionera-SPEED),实现了100%成功的无等待时间的自动版Muller-Rudin过程。 

    德国慕尼黑技术大学的Friedrich Simmel教授评价:

    “并行的Nanion Orbit 16平台对于我们的项目非常关键,因为它让我们提高了数据通量,并且为我们加速优化将合成的DNA通道整合到脂双层中的条件。MECA中的微小凹槽也帮助我们能直接证明分子通过通道的转移过程,这样我们能非常容易的证明在顺式单元中分子的聚集。” 

    Nanion技术公司的首席运营官 Niels Fertig博士继续说:

    “我们很高兴的看到Orbit16展示了它强大的在纳米孔研究方面上的潜能,尤其是有了令人兴奋的DNA折叠通道的新发展之后。正如预料的,Orbit的一些特征,例如自动化、低噪音和并行记录等等使得这项技术非常适合离子通道和纳米孔领域的。我们只是今年才介绍Orbit,几个月前才开始发货,因此现在就能看到用户发表了如此高质量的文章实在令人兴奋.” 

    弗莱堡大学Ionera项目组长 Gerhard Baaken博士也加进来:

    “Simmel教授的小组已经是最早的MECA芯片测试者。我们也很高心的看到他们对它的满意和他们在卓越的《科学》杂志上发表文章的极度兴奋,文章中MECA装置和Ionera-SPREED自动脂双层形成发挥了决定性的作用,加速和简化了研究过程。Nanion公司的Orbit16是将MECA带向市场的理想平台,我们期待着2013年全面的商业发布”


    Orbit16已在2012年初发布,第一套设备已经落户。Orbit16可以形成和记录含有溶液的脂双层,它使用Ionera公司的MECA或不含溶液的Nanion公司GUV式的脂双层方案。后者已经用于Port-a-Patch.


  • 08.11.2012 | Nanion Introduces NPC-Certified Cell Lines

    Munich, Germany, November 08, 2012; Nanion’s automated patch clamp platforms are known for their high cell compatibility, even for primary cells and stem cells. Nanion now introduces “Nanion Approved Cells”, where commercially available cell lines from several providers have been evaluated and certified based on cell and platform performance. The approved cells can be directly purchased through Nanion, so that Nanion’s customers get a complete package of APC platform and validated assay. 
    A large number of cell lines from several providers, including Millipore and CreaCell have been validated on Nanion’s three automated patch clamp platforms, the Port-a-PatchPatchliner, and the SyncroPatch 96. Parameters such as average seal-resistance, access resistance, cell recording longevity, ion channel expression and success rates for completed recordings were investigated and documented in a standardized way. Success rates for completed recordings were typically above 70%. With Nanion Approved Cells, the user can rest assured that the assay will run optimally, with minimal or no assay development required. 

    Atsushi Ohtsuki, Customer Support Manager, Nanion Technologies, Japan says:
    "The Nanion Approved Cells will be much appreciated by Japanese customers, since the optimization work already has been done by Nanion Technologies, which saves time and reduces the risk of an investment. Additionally, it is also a guarantee, that the customers will encounter minimal problems when starting a new assay on Nanion\"s automated patch clamp platforms."

    Dr. Niels Fertig, CEO of Nanion, continues:
    "The certification of commercially available cell lines makes it easier for existing and new customers to invest in new cell lines and our platforms without having to worry about lengthy assay development. It is a well-known fact that Nanion\"s platforms show great compatibility with a broad range of cells and ion channels, which also is confirmed by the long list of Nanion Approved Cells and scientific publications in high impact journals such as Nature or PNAS. Nanion also certifies cell lines on-demand, meaning that if a customer has a particular cell line of interest, we evaluate and document the cell performance on our platforms, free of charge."

    About Nanion Approved Cells
    Nanion Approved Cells are commercially available cells, certified on Nanion\"s three automated patch clamp platforms. Cell and platforms performance as well as ion channel current expression is thoroughly investigated and summarized in a data sheet. The approved cells can be directly purchased from Nanion, so that Nanion\"s customers get a package of APC platform and validated assay. Nanion also does cell line certification on-demand, if the cell line of interest cannot be found in the list of approved cells. The full list of tested cell lines can be found on Nanion\"s website.


    For the full press release please click here
       
  • 29.06.2012 | 新的Patchliner文章发表:迈向早期安全性评价的新标准


    慕尼黑,2012,06,29,在最近的刊物上,瑞士巴塞尔霍夫曼罗氏的科学家就Patchliner用于研究影响hERG通道以及通常涉及药物安全责任问题的心脏病离子通道的药物安全性检测做出了评价。在研究中,实验在生理温度下进行(35 – 37°C),获得的数据同传统膜片钳上记录的药理学数据相比较显示了很好的相关性

    Liudmila Polochuk博士总结道:“迈向早期安全性评价的新金标准:在Patchliner上进行的自动化温度控制的hERG测试”

    “……基于这些结果,Patchliner代表了一种创新的用于指导hERG分析的全自动电生理平台,它极大地增加了通量,在生理温度的操作上具有优势。它允许快速、精确、直接的通道功能评定来确认潜在的致心律失常的副作用和建立一种新的标准用于离子通道研究的药物安全性检测。”

    Dr. Polunchuk也说:

    “Patchliner工作站提供稳定的电流和37℃下的高质量千兆级封接记录。基于这些可信的结果,这个全自动的电生理工作站可用于进行生理温度下新化合物的先进的hERG检测和最终可能会成为在安全药理学研究离子通道的一种新的黄金标准。”

    需要更多的研究信息,点击这里下载全文。

    Patchliner和温度控制

    Patchliner是一个高质量、全自动的膜片钳平台,支持两种温度控制模式:稳定的生理温度或者加样枪中应用试剂的快速加热。在后者情况下,最高可达65℃的溶液能被加入到膜片钳细胞上。

    需要更多关于Patchliner的信息,点击这里

    需要更多关于温度控制的信息,点击这里


  • 26.02.2012 | Nanion Acquires the SURFE2R Technology for Transporter Protein Analysis

    Munich, Germany, February 26, 2012; Nanion acquires the well-established SURFE2R technology, allowing state-of-the-art measurements of transporter protein activity and function. The SURFE2R technology is an excellent enhancement to Nanion’s existing products which until now covered ion channels and nanopores.
    Nanion Technologies is one of the leading providers of high quality automated patch clamp systems. Nanion’s efficient and versatile products drastically improve the data output in patch clamp-based ion channel screening, safety testing and scientific research. Since 2003, Nanion has launched three automated patch clamp platforms, the Port-a-Patch (2003), the Patchliner (2006), the SyncroPatch 96 (2010), and recently introduced the Orbit 16 – a device for parallel bilayer recordings. Existing products target ion channels and nanopores in cell- and cell-free membranes for highly detailed information about kinetics, function, and compound pharmacology.

    Dr. Niels Fertig, CEO of Nanion Technologies, continues:
    “By acquiring the SURFE2R technology developed by IonGate / Scientific Devices Heidelberg, Nanion enters yet another market segment. It is an excellent addition to our product portfolio and a unique platform since it allows direct measurements of transporter activity and function. Further on, the platform has been validated with a wide variety of membrane preparations ranging from bacteria to native cells and cell lines. With this acquisition, Nanion becomes a one-stop-shop for functional membrane protein analysis, extending its product portfolio from screening instrumentation for ion channels and nanopores to now also include transporter proteins. “


    The SURFE2R product line will be launched during the second half of 2012.

    Download the full press release here.

    For more information click here.

  • 21.02.2012 | Nanion Introduces the Orbit 16 – a Pioneering Device for Parallel Lipid Bilayer Recordings

    Today, Nanion announces the introduction of a completely new product line for efficient analysis of bilayer-reconstituted ion channels and nanopores. The first of these, the Orbit 16, allows for automated formation of, and recordings from 16 bilayers in parallel, combining efficient data generation and ultra-high data quality. The Orbit 16 takes the pain out of bilayer recordings and facilitates efficient data generation through 16 parallel recordings.

    Bilayer recording is a well-established technique for in-depth studies of biophysical properties of ion channels and is particularly suited for functional studies on proteins residing in intracellular membranes. Moreover, this technique supports a host of powerful emerging analytical techniques using biological nanopores as molecular sensors.
    Despite its proven value, bilayer recording can be very frustrating due to the capricious nature of lipid bilayers which have to be formed manually one by one and which often lack stability. The Orbit 16 speeds up the entire process by the rapid and simultaneous formation of 16, highly stable micrometer-sized bilayers and allows subsequent parallel recordings, thereby enabling efficient data generation. For increased experimental flexibility, two different recording chips are available; either Ionera\"s microelectrode cavity array (MECA) - or Nanion\"s-recording chips for work on (proteo-) liposomes, the latter as known from the Port-a-Patch.

    Dr. Gerhard Baaken, University of Freiburg, Germany, and founder of Ionera, says:
    “Ionera is the developer and will be the provider of the Micro Electrode Cavity Array chip substrates, used with the Orbit 16. We have recently published a study showing that the MECA supports high-resolution polymer sizing with a single biological nanopore (alpha-haemolysin) - one of the most exacting tasks in bilayer recording- in a parallel format. We think that the Orbit 16 will be an ideal environment for our MECA-16 chip and will prove to be a highly enabling technology for bilayer and nanopore research due to the ease of bilayer formation and signal to noise quality of recordings. Thanks to the parallelism of the recordings, the researcher can in most cases obtain data and statistics from one single run.

    Dr. Niels Fertig, CEO of Nanion Technologies, continues:
    “With the Orbit 16, Nanion enters a new market segment. The Orbit 16 has great potential since it makes bilayer recordings more efficient and accessible to a wider audience. The Orbit 16 offers excellent data quality, i.e. low noise at high bandwidth, in combination with an unmatched data throughput. We anticipate that these features make the Orbit 16 appealing to the ion channel- and nanopore-communities, or anyone who wants to enter the field of bilayer recordings. “

    The Orbit 16 has its public premiere at the Biophysical Society Annual Meeting, in San Diego, CA, USA, February 26 – 29, 2012.

    Download the full press release here.

  • 15.01.2012 | Nanion celebrates 10th anniversary - still with a strong focus on new innovations



     Nanion - 10 years of automated patch clamp
    Munich, Germany, January 15, 2012; Today, Nanion celebrates 10 years of innovation, scientific product development and successful roll-outs of several product families. Nanion is a success story of organic, revenue-based company growth and dedicated young professionals. 
    10 years ago, Nanion Technologies started out in a small loft at the Institute of Physiology of Ludwig-Maximilian’s University in Munich. Since then, Nanion has grown from 2 to 40 employees and has successfully launched and established four different product families for ion channel drug discovery and research. 

    The Port-a-Patch - launched in 2003 - was Nanion’s first product, and is known as the world’s smallest patch clamp rig. It earned great acclaim by making patch clamp accessible to non-experts. The fully automated patch clamp robots, the Patchliner (2006) and SyncroPatch 96 (2010), have been well received within the pharmaceutical industry because of the high data quality, cost-efficiency and experimental flexibility offered. The platforms are also employed for top-notch academic research, resulting in publications in journals such as Nature, Nature Protocol, Science Signalling and PNAS. 


    Nanion is a strongly innovation-driven company with several product launches planned for 2012. 

    Dr. Niels Fertig, co-founder and CEO of Nanion, says:
    “Nanion’s strong and sustained growth is based on innovative technology, high performance instrumentation and close customer relations. It has been a really exciting journey gradually turning from start-up into a more mature company with everything that it entails. We are extremely happy about, thankful for and proud of what we have achieved so far and very much look forward to the next decade of product development, science and business growth!”

    Michael George, CTO and co-owner of Nanion Technologies continues:
    “2012 will be a thrilling year, with several different new products in the pipeline. At Nanion, innovation never ends. This is true as much for brand new ideas and concepts as for existing products. Our customers continue to inspire us to develop hardware and software allowing novel experimental possibilities or just making life easier for the every-day-user. It is very rewarding to get the feedback that we are developing state-of-the-art products enabling completely new strategies for ion channel screening and research.”

    Download the full press release here.

    Read more: 
    “Nanion – 10 years of automated patch clamp”
  • 30.11.2011 | Nanion’s SyncroPatch 96 Convinces Big Pharma Automated Patch Clamp Users

    Munich, Germany, November 30th, 2011; Nanions ion channel screening platform, the SyncroPatch 96, has been well received within the pharmaceutical industry during the past 12 months. Experienced automated patch clamp users decide in favor of the SyncroPatch 96 because of its high throughput and cost-efficiency in combination with reliable pharmacology for heterologous voltage- and ligand-gated ion channel targets.
    The SyncroPatch 96 is Nanion’s high throughput screening platform, capable of generating 9000 data points per day. Since the launch earlier this year, the SyncroPatch 96 platform has been validated with a wide variety of ion channels and cell types, including challenging ligand gated channels such as α7 nicotinic acetylcholine receptors.

    Dr. Adam Hendricson, Lead Evaluation, Bristol-Myers Squibb, CT, USA, says:
    “The flexibility of the SyncroPatch 96 to run ligand-gated assays without sacrificing throughput or fidelity relative to voltage-gated channels really sets it apart in the gigaseal auto-EP space. When considering different platforms, the SyncroPatch was the only system that met all our critical criteria: >50% giga-seal across multiple cell lines, minimal chip priming and cell-handling, rapid solution exchange for fast agonists, internal solution exchange, ability to multiplex cells in a run, compatibility with external robotic automation, and a highly competitive cost per data point. We run the SyncroPatch on a daily basis and are very happy with its performance and efficiency, and with the excellent, highly responsive applications support offered by Nanion.”

    Dr. Henning Draheim, Boehringer-Ingelheim, Germany, continues:
    “We carefully researched the market before looking closer at selected APC platforms that may match our internal criteria. We were very impressed by the SyncroPatch 96 system’s flexibility and data quality when testing it on-site, finding that it really performs “as advertised” and definitely fits our needs. In addition, Nanion performed a blind study on the SyncroPatch, testing 22 of our compounds, using a protocol addressing the block of sodium channels in their inactivated state. The obtained compound pharmacology was compared to our manual patch clamp data and the match was fantastic! For me, it was then a straightforward decision for the SyncroPatch 96 and of course it is great when the data speaks for itself when one needs to convince the upper management to purchase state-of-art equipment.”

    Niels Fertig, CEO of Nanion Technologies, ads:
    “We see a general trend that experienced APC users decide for the SyncroPatch 96. For us, this is a clear indication that the platform delivers what industrial screeners want, in terms of throughput, experimental capabilities and data reliability. Secondly, experienced users challenge the platforms harder – which we welcome, since it proves the capabilities as well as limitations of the tested platforms. As always, we listen carefully to what our customers tell us, to match their hardware and software requirements. At the moment, we’re very busy installing the SyncroPatch 96 worldwide, and we foresee very positive developments in 2012.”

    Nanion offers demonstrations of the SyncroPatch 96 at the head quarters in Munich, Germany, and North Brunswick, NJ, USA, or at the customer site.

    Download the full press release here
  • 11.11.2011 | Nanion successfully performs automated patch clamp recordings from stem cell-derived neurons

    Human iPS cell-derived neurons (iCell neurons) from Cellular Dynamics International were successfully used on Nanion’s 8-channel Patchliner. 
    To our knowledge, this is the first time stem cell derived neurons have been used on an automated patch clamp device. 

    Initial experiments showed the presence of voltage-gated Na+, voltage-gated K+ and GABA receptor-mediated currents from these cells. Nanion will continue to work with Cellular Dynamics International to further characterize these cells using the Port-a-Patch, Patchliner and SyncroPatch 96.

    Visit Nanion’s booth (#601) at the Society for Neuroscience meeting in Washington D.C. to learn more!  

    Download the application note here
  • 24.10.2011 | Nanion opens China office in Beijing

    Today, Nanion announces the opening of yet another branch. To meet the needs of the rapidly expanding number of customers in China, the dedicated sales- and support team in Beijing now opens the doors to Nanion Technologies China. 
    Nanion successfully entered the Chinese market over five years ago, and the installed base of Patchliner and Port-a-Patch instruments has grown constantly ever since. To cover the increasing interest and activities within the fields of ion channel screening, scientific and contract research, the subsidiary Nanion Technologies China is now officially open.

    Andy Di, General Manager, Nanion Technologies China, says:
    “Nanion’s customer base in China has grown rapidly over the past couple of years. Nanion’s products are very appreciated here because of their vast experimental freedom paired with increased throughput and affordable consumables. Because of their high quality and reliability, products like the SyncroPatch 96, the Patchliner and the Port-a-Patch are attractive for both industrial screening purposes and for dedicated academic research.” 

    Niels Fertig, CEO of Nanion Technologies GmbH, continues:
    “Because of the growing Chinese market and customer base, it was a natural step to expand in China. With the new subsidiary we are able to cover the ever-increasing demand for product demonstrations and installations as well as to continue giving our Chinese customers premium support. We definitely feel that we have the right people in place for this important step in Nanion’s history, and we look forward to a fruitful collaboration with the Nanion team in China. “

    Nanion Technologies China offers live product demonstrations and customer training in Beijing and Shanghai, or at the customer site.

    Download the full press release here
  • 16.09.2011 | Nanion’s automated patch clamp platforms show unparalleled results using stem cell derived cardiomyocytes

    The Patchliner and the SyncroPatch 96 have successfully been used for compound analysis under current- and voltage clamp recording conditions using different stem cell-derived cardiomyocytes. The exceptional cell-platform-compatibility and the unique experimental possibilities offered by Nanion’s platforms open up whole new avenues for compound safety testing.
    Pluripotent stem cell-derived cardiomyocytes have tremendous potentials for cardiac safety and efficacy testing of drug candidates. By offering an authentic cellular environment they are closer to the actual physiological situation compared to cell lines with over-expressed ion channels. All Nanion’s patch clamp platforms, the Port-a-Patch, the Patchliner and the SyncroPatch 96, show exceptional compatibility with stem cell-derived cardiomyocytes provided by Axiogenesis, CDI and Geron/GE Healthcare.

    In a joint publication of Nanion and Axiogenesis (Journal of Biomolecular Screening, 2011 July 20), drug-induced modulation of cardiac action potentials using the Port-a-Patch and Patchliner were shown for the first time. Stem cell-derived cardiomyocytes have also been investigated on the SyncroPatch 96, recording from 96 cells in parallel under voltage clamp conditions. Stable whole-cell recordings were obtained with high success rates and expected cardiac currents were recorded (K+, Ca2+, Na+).

    Ralf Kettenhofen, Senior Scientist of Axiogenesis, Cologne, Germany, says:
    “At Axiogenesis, we were very impressed of the high success rates quickly obtained with Nanion’s platforms. 
    In our view, the combination of an in vitro cardiac cell model together with higher throughput patch clamp screening technology such as the Patchliner, allows for a cost effective cardiotoxicity prediction in a physiologically relevant cell system.”

    Axiogenesis is a provider of pure rodent embryonic stem cell-derived cardiomyocytes (Cor.At®) which have been proven to be a predictive tool in preclinical cardiac safety assessment and drug discovery and development. The Cor.At® cardiomyocytes will now be complemented by human induced pluripotent stell cell-derived (Cor.4U®) cardiomyocytes, which will be launched in Q1 2012.

    Niels Fertig, CEO of Nanion Technologies continues:
    “Over the past two years, the interest from the pharmaceutical industry in using stem cell-derived cardiomyocytes for safety testing purposes has grown dramatically. To meet this need we have developed our platforms to fit experimental requirements and industry quality standards. It is up to the user to decide: routine analysis in voltage clamp mode, or investigating the compound effect on action potentials since both screening modes are possible. No other APC platform on the market can compete with that at today’s date.”

    Download the full press release here. logo_pdf(49 kB)
  • 21.07.2011 | Breakthrough discovery published in PNAS: Dissected, pore-only Nav's measured on the Port-a-Patch

    Voltage-gated sodium channels have proven very difficult to crystallize and thus also difficult to obtain a detailed structure of the functional protein. Using a reductionist approach described in the recent PNAS paper, Professor Dan Minor and his research group at the University of San Francisco, USA, together with Nanion scientists, are on their way to reveal the structural impact on selectivity and permeability of sodium channel pores.
    In the paper published in PNAS, David Shaya and co-authors show bilayer recordings of functional, pore-only Nav channels. By reducing the complexity of the voltage-gated sodium channels, for example by removing the voltage sensing domain in the extracellular part of the ion channel complex, the researchers hope to be able to crystallize the pore forming domains, as a step towards revealing the full structure of Nav as well as Cav-channels. Indeed, a single-point mutation of the pore-only Nav’s showed altered pore selectivity towards calcium ions.

    “It meant a lot of hard work to successfully reconstitute the three functional Nav pore-only channels into lipid bilayers. Luckily, the Port-a-Patch offers fast and straightforward means for ultra-high-quality electrophysiological recordings from ion channels residing in solvent free, artificial bilayers, and enabled me to find the right conditions for the dissected Nav-channels. It was a really cool feeling, to be the first person in the world to record and characterize these ion channels.” 
    says Dr. Mohamed Kreir, Application Scientist at Nanion, who did the electrophysiology recordings of the dissected sodium ion channel pores.

    The method described in this paper, implies a general way to study biophysical aspects of pore structure, and for example the modification by small molecules. The authors suggest that this might be an attractive model for the pharmaceutical industry to reveal compound effects on the pore domain of basically any voltage gated ion channel.

    Visit Professor Minor’s web page.
    Download the full paper.
    For more Nanion-related papers, visit Downloads.
    Find more Port-a-Patch information.
  • 06.06.2011 | BMS reports successful screening of advanced ligand gated ion channel targets on SyncroPatch96

    Accurate screening of ligand gated channels, high throughput and data quality is now a possible combination thanks to the SyncroPatch 96. 

    The SyncroPatch 96 is a full-blown screening platform supporting giga-seal whole-cells recordings from 96 cells in parallel. Allowing full dose response analysis from the individual cells, the SyncroPatch 96 is ideal for studies of both ligand- and voltage-gated ion channels. High quality recordings together with brief and precise compound application grant minimal false-positives and negatives in the drug screening process. 
    Find out more by downloading the NEW SyncroPatch 96 product sheet! 

    Adam Hendricson, Ph.D., Applied Biotechnology & Lead Evaluation, Bristol-Myers Squibb, Wallingford, CT, USA, says:

    “The flexibility of the SyncroPatch 96 to run ligand-gated assays without sacrificing throughput or fidelity relative to voltage-gated channels really sets it apart in the gigaseal auto-EP space.”

    Dr. Adam Hendricson’s will be presenting at the following meetings: 

    “Changing the Game in Ion Channels – Ultra High-Throughput in Automated Electrophysiology”
    World Pharma Congress, Screening Summit: Tools and Technologies for HTS, Philadelphia, PA, USA 

    “Bridging the Gaps in Ion Channel Hit-to-Lead with SyncroPatch 96: Ultra-High Throughput Auto-EP”
    Aurora Ion Channel Retreat 2011, Vancouver, Canada


    Ask us for more data, information or a quote by sending an email toinfo@nanion.de.


    Download the new SyncroPatch 96 Product Sheet here! (780kB)


  • 04.03.2011 | Nanion’s Patchliner exceptionally well received by academic ion channel core facilities

    Munich, Germany, March 4th, 2011; The new year has started well for Nanion; in the first weeks of 2011 more than five Patchliners were sold and shipped to academic institutions, intended for advanced ion channel research and screening projects, and are soon to be followed by the first SyncroPatch 96 shipment and installation.

    The Patchliner, a highly versatile patch clamp screening platform for increased throughput, has been on the market since 2006. Patchliner customers are evenly distributed over pharmaceutical industry, contract research organizations and academic institutions because of the flexibility and increased throughput of the platform.
    Again highlighted by the recent sales, the Patchliner is a much appreciated tool for academic research, mainly because of the high data quality obtained with the platform, and its vast experimental freedom.

    Together with three additional Principal Investigators, Dr. Todd Scheuer and Dr. William Catterall invested in both the Patchliner and the Port-a-Patch to form a core facility for ion channel screening and research at the University of Washington, Seattle, USA. 
    Dr. Todd Scheuer, Research Professor at the Department of Pharmacology, University of Washington, Seattle, says:
    “We invested in the Patchliner because of its great experimental flexibility. The diversity of our research projects requires a platform capable of high performance with a multitude of ion channels and cells, as well as experimental possibilities such as action potential- or primary cell recordings.” 

    In the southern hemisphere, Dr. Steven Petrou, Associate Director at the Florey Neuroscience Institute, and Associate Professor at the Centre for Neuroscience, The University of Melbourne, Australia, invested in multiple Patchliners for the ion channel core facility there. 
    Dr. Steven Petrou says:
    “We recently bought several Patchliners to cover the needs of our neuroscience research projects and to establish an ion channel core facility for the wider ion channel research community. Indeed, the Patchliner has unique experimental features including temperature control, internal perfusion and fast solution exchange. This in combination with supporting giga-Ohm seals and having a throughput corresponding to 100 dose responses per day convinced us that Patchliner will be of great use in our current, but also future research projects.”

    Dr. Niels Fertig, CEO of Nanion says:

    “We are of course very pleased with this year’s sales trend, which reflects the customers’ appreciation of our high fidelity patch clamp platform and the strong scientific background of our support team. As a consequence, we have expanded the US-office to match the demand for demonstration and to cover possible assay support. Further, the installation of another five Patchliners in top-notch academic laboratories confirms its strength and unparalleled experimental features.”

    Download the full press release in English here  logo_pdf(69 kB)

  • 01.02.2011 | Nanion expands the US-office

    North Brunswick, NJ, USA, February 1st, 2011; Nanion welcomes Dr. Joerg Oestreich to the team. With Dr. Oestreich’s strong background in electrophysiology screening assays, Nanion continues to offer premium support for the US-market.

    Dr. Joerg Oestreich, previously  Study Director at Chantest Corporation, Cleveland, OH, has a solid background in electrophysiology and high throughput drug discovery. Dr. Oestreich received his Ph.D. at the University of Texas at Austin, and continued with post-doc studies at Harvard Medical School, Boston, MA within the field of electrophysiology. Having experience with a multitude of ion channels targets and cellular assays, Dr. Oestreich is a great match for the Nanion team.

    Rodolfo Haedo, General Manager of Nanion Inc., says:
    “With the rapidly growing number of Patchliner and Port-a-Patch customers, Dr. Oestreich is a needed and welcome contribution to the US-team. I am convinced that his valuable expertise and professional experience will come very handy for covering the ever-increasing demand of product demonstrations, workshops and assay support.”

    Joerg Oestreich says:
    “I find Nanion’s vision and product portfolio very convincing; the Port-a-Patch and Patchliner are excellent and important research platforms that are not only suited for industrial ion channel research, but also for academia due to their unmatched flexibility and data quality.  They are greatly complemented by the SyncroPatch 96, a screening platform covering the industry’s need for higher throughput and quality in safety testing and drug screening efforts. In addition, Nanion has a very innovative, dynamic, and dedicated team that if required will go through tremendous efforts to  support their customers, and on a personal level is also very pleasant to work with.

    Niels Fertig, CEO continues:
    “I am happy to welcome Dr. Joerg Oestreich to the team! Despite of the global economic crisis, we see a clearly positive trend in the US sales of our robotic platforms. 2011 will be a very exciting year, especially on the US- and Asian markets with the upcoming installations of the SyncroPatch 96.”